Canopy Growth (CGC) Q2 2027 Earnings Call Transcript

Canopy Growth (CGC) reported Q2 2027 revenue of $81.4M, up 22% YoY, driven by 30% cannabis segment growth. Medical cannabis and international markets showed momentum, while Storz & Bickel revenue fell 44% YoY to $50.1M. The company expects improved yields and EU GMP certifications to boost growth and margins. Adjusted EBITDA loss narrowed to $2.9M, with a target of profitability in H2 2027.

Original reporting
Published Nov 6, 2026, 7:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Canopy Growth (CGC) Q2 2027 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CGCNeutralMed
01

Why it matters

Traders can update expectations for gross margin trajectory (VAC reimbursement reduction), segment mix (international cannabis growth), and forward operating leverage from cultivation yield and EU GMP certifications that enable broader European product categories.

02

Market read

Company-specific earnings disclosures and explicit cultivation yield targets can drive repricing of FY28 profitability expectations, despite reimbursement-related margin pressure.

03

What to watch

Storz & Bickel revenue is down 44% year over year, so consolidated momentum may remain sensitive to consumer spending and product-cycle execution in that segment.

Relevance 7/10Novelty 6/10Timing: during/after the Q2 2027 earnings call, positioning for Q3 seasonality and FY28 cultivation ramp

Background

The transcript discusses Canopy Growth’s Q2 FY27 performance across its cannabis segment and Storz & Bickel, including cultivation improvements after acquiring MTL and the impact of the VAC reimbursement cap.

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Canopy’s Q2 FY27 call discloses revenue growth, gross margin drivers from the VAC reimbursement cap, and a Kincardine yield plan of 25% to 30%.

Expected impact

Likely mixed reaction, with upside bias from the Kincardine yield/quality ramp and international momentum, offset by continued gross margin headwinds from the VAC reimbursement reduction.

Evidence & confidence

The article contains multiple company-specific operating datapoints (net revenue, segment growth, gross margin drivers, synergy run-rate, and explicit yield targets) that can change near-term expectations, but it also emphasizes a known reimbursement-driven margin drag.

Market effects

Signals ongoing normalization of Canadian medical economics post-reimbursement changes and continued shift toward international and product-category expansion via EU GMP.

Emphasizes Europe expansion path (Smiths Falls EU GMP) and UK medical market entry, which may influence regional cannabis supply and pricing expectations.

Highlights cross-border regulatory manufacturing readiness (EU GMP) as a gating factor for scaling medical cannabis categories beyond flower.

Counterpoint

The yield target (25% to 30%) is contingent on execution and timing, while the VAC reimbursement reduction is a direct, potentially persistent margin headwind.

Key entities

  • Canopy Growth

    Subject of the earnings call transcript, providing Q2 FY27 results, margin drivers, cultivation yield targets, and EU GMP certification updates.

  • Storz & Bickel

    Vaporization segment discussed with revenue decline and margin improvement tied to cost efficiencies under new management.

  • MTL Cannabis

    Acquisition referenced as a driver of cultivation expertise and brand momentum in Canada.

Related articles

$CGCMedAI 8/10

Canopy Growth Corporation Q2 2027 Earnings Call Summary

Canopy Growth reported Q2 2027 results, highlighting a 141% YoY increase in international cannabis revenue and a 44% decline in Storz & Bickel revenue due to economic uncertainty. The company aims for positive adjusted EBITDA in H2 2027, with cultivation improvements expected to boost flower production by 25-30% in early 2028. Canopy also secured EU GMP certification, enabling expansion into European markets beyond dry flower.

$CGCMed

Canopy Growth Q2 Earnings Call Highlights

Canopy Growth reported Q2 revenue growth in Canada and plans to build a dedicated sales force. Storz & Bickel revenue declined 4% but expects a strong Q3. Cultivation improvements aim for 25-30% yield increase. Adjusted gross margin fell to 31% from 33% due to VA reimbursement rate changes. Cash reserves were CAD 320 million as of September 30. The company may pursue a reverse stock split to maintain Nasdaq compliance.